Fimepinostat in Treating Brain Tumors in Children and Young Adults (NCT03893487)
A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
🩺 Plain-English Summary (8th-Grade Level)
This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Who can join: Review the eligibility criteria below.
Location: Children's Hospital Los Angeles (CHLA) — Los Angeles, California
Age range: 3 Years to 39 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Children's Hospital Los Angeles (CHLA) — Los Angeles, California
- Rady Children's Hospital — San Diego, California
- University of California, San Francisco — San Francisco, California
- Children's National Medical Center — Washington D.C., District of Columbia
- University of Florida — Gainesville, Florida
- Lurie Children's Hospital of Chicago — Chicago, Illinois
- Johns Hopkins Hospital — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Michigan Hospital — Ann Arbor, Michigan
- Children's Minnesota Research Institute — Minneapolis, Minnesota
- Washington University in St Louis — St Louis, Missouri
- Nationwide Children's — Columbus, Ohio
- Oregon Health and Science University — Portland, Oregon
- Children's Hospital of Philadelphia (CHOP) — Philadelphia, Pennsylvania
- St. Jude Children's Research Hospital — Memphis, Tennessee
- Texas Children's Hospital — Houston, Texas
- University of Utah, Children's Primary — Salt Lake City, Utah
- Seattle Children's Hospital — Seattle, Washington
- The University Children's Hospital in Zurich — Zurich, Canton of Zurich
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diffuse Intrinsic Pontine Glioma
- Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors — Seattle, Washington
- FUS Etoposide for DMG — New York, New York
- Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma — Washington D.C., District of Columbia
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG — Orange, California
- C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) — Houston, Texas
Explore by condition: All Diffuse Intrinsic Pontine Glioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.